| # | Drug | Count |
|---|---|---|
| 0 | CYCLOPHOSPHAMIDE | 2336 |
| 1 | CYCLOPHOSPHAMIDE FOR INJECTION | 2336 |
| 2 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 2336 |
| 3 | LENALIDOMIDE | 2178 |
| 4 | RITUXIMAB | 1445 |
| 5 | ETOPOSIDE | 1218 |
| 6 | DOXORUBICIN | 1189 |
| 7 | PREDNISONE | 1141 |
| 8 | METHOTREXATE SODIUM | 1128 |
| 9 | DEXAMETHASONE | 1120 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | IBRITUMOMAB TIUXETAN | 98 | 0.0643 |
| 1 | CARMUSTINE | 301 | 0.0638 |
| 2 | INDIUM IN -111 PENTETREOTIDE | 6 | 0.0469 |
| 3 | MITOXANTRONE HYDROCHLORIDE | 237 | 0.0377 |
| 4 | IDECABTAGENE VICLEUCEL | 38 | 0.0306 |
| 5 | BREXUCABTAGENE AUTOLEUCEL | 65 | 0.0301 |
| 6 | AXICABTAGENE CILOLEUCEL | 295 | 0.0290 |
| 7 | LUSPATERCEPT | 75 | 0.0287 |
| 8 | MELPHALAN HYDROCHLORIDE | 722 | 0.0285 |
| 9 | AZACITIDINE | 780 | 0.0259 |
| # | Drug class | Count |
|---|---|---|
| 0 | Alkylating Drug [EPC] | 2907 |
| 1 | Corticosteroid [EPC] | 2652 |
| 2 | Thalidomide Analog [EPC] | 2226 |
| 3 | Nucleoside Metabolic Inhibitor [EPC] | 2002 |
| 4 | CD20-directed Cytolytic Antibody [EPC] | 1519 |
| 5 | Platinum-based Drug [EPC] | 1447 |
| 6 | Topoisomerase Inhibitor [EPC] | 1234 |
| 7 | Folate Analog Metabolic Inhibitor [EPC] | 1028 |
| 8 | Nonsteroidal Anti-inflammatory Drug [EPC] | 792 |
| 9 | Microtubule Inhibitor [EPC] | 626 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CD38-directed Cytolytic Antibody [EPC] | 185 | 0.0316 |
| 1 | CD19-directed Chimeric Antigen Receptor [EPC] | 295 | 0.0290 |
| 2 | Erythroid Maturation Agent [EPC] | 75 | 0.0287 |
| 3 | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | 493 | 0.0230 |
| 4 | Iron Chelator [EPC] | 479 | 0.0164 |
| 5 | Thrombopoietin Receptor Agonist [EPC] | 246 | 0.0162 |
| 6 | Topoisomerase Inhibitor [EPC] | 1234 | 0.0160 |
| 7 | Complement Factor D Inhibitor [EPC] | 4 | 0.0129 |
| 8 | Alkylating Drug [EPC] | 2907 | 0.0119 |
| 9 | Actinomycin [EPC] | 25 | 0.0113 |